Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsGlobe Newswire • about 1 month ago
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Share to Feed
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), ( Panbela ), a clinical stage company developing disruptive therapeutics for the treatment of patients...
Panbela Therapeutics regains compliance with Nasdaq...
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), ( Panbela ), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Therapeutics (NASDAQ:PBLA Get Free Report) and NeuroSense Therapeutics (NASDAQ:NRSN Get Free Report) are both medical companies, but which is the better investment? We will...
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent...
Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expecting approximately $9.0 million in gross proceeds.
read more...
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent...
Panbela Therapeutics, Processa Pharmaceuticals among healthcare movers...